V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Akebia Therapeutics Executive Compensation (FY25)

AKBA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
John Butler
Latest say-on-pay support
=
June 17, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Akebia Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 22, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Akebia Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
250 figures on this page: 243 cited to the filing that reported them, 7 calculated from figures it prints. See the citations

More on Akebia Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Butler: $4,260,114 → $5,652,339 (32.7% higher)
Say-on-pay support: 73.9% → 63.7% (10.2 points lower)
CEO pay ratio: 17:1 → 21:1 (23.5% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Akebia Therapeutics' chief executive and what were they paid?
John Butler, President and Chief Executive Officer, received $5,652,339 in total compensation for fiscal 2025. Butler's total was 32.7% higher than the $4,260,114 reported for fiscal 2024.
What was Akebia Therapeutics' say-on-pay result?
The say-on-pay proposal drew 63.7% of votes cast for or against in favor at the meeting held June 17, 2026 for fiscal 2025.
Which companies are in Akebia Therapeutics' peer group?
The disclosed peer group includes Ardelyx, Inc., Coherus BioSciences, Inc., Collegium Pharmaceutical, Inc., Enanta Pharmaceuticals, Inc. and Esperion Therapeutics, Inc., among others.
What is Akebia Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 21:1, against median employee compensation of $270,410.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Butler
President and Chief Executive Officer
◇—◇◇◇—◇◇
David Spellman
Senior Vice President, Chief Financial Officer and Treasurer
◇◇◇◇◇—◇◇
Steven Burke
Senior Vice President, Chief Medical Officer
◇—◇◇◇—◇◇
Michel Dahan
Senior Vice President, Chief Operating Officer
◇—◇◇◇—◇◇
Nicole Hadas
Senior Vice President, Chief Legal Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Butler
President and Chief Executive Officer
◇—◇◇◇—◇◇
Ellen Snow
Former Senior Vice President, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Michel Dahan
Former Senior Vice President, Chief Operating Officer
◇—◇—◇—◇◇
Steven Burke
Senior Vice President, Chief Research & Development and Medical Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Butler
President and Chief Executive Officer
◇—◇◇◇—◇◇
Nicholas Grund
Senior Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Steven Burke
Senior Vice President, Chief Research & Development and Medical Officer
◇—◇◇◇—◇◇
Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
◇—◇◇◇—◇◇
Michel Dahan
Former Senior Vice President, Chief Operating Officer
Departed during or after this year
◇—◇◇◇—◇◇
Ellen Snow
Former Senior Vice President, Chief Financial Officer and Treasurer
Departed during or after this year
◇—◇◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Butler
President and Chief Executive Officer
◇—◇◇◇—◇◇
Steven Burke
Senior Vice President, Chief Research & Development and Medical Officer
◇—◇◇◇—◇◇
Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
◇—◇◇◇—◇◇
Nicholas Grund
Senior Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Erik J. OstrowskiRSU◇——◇——◇
John P. ButlerRSU◇——◇——◇
Nicholas P. GrundRSU◇——◇——◇
Steven K. BurkeRSU◇——◇——◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Steven BurkeOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
John ButlerRSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Erik OstrowskiRSU◇◇——
Option◇—◇—
Option◇—◇—
Nicholas GrundOption◇—◇—
RSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer · Severance agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
John Butler
President and Chief Executive Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Nicholas Grund
Senior Vice President, Chief Commercial Officer · Severance agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Steven Burke
Senior Vice President, Chief Research & Development and Medical Officer · Severance agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Adrian Adams
Board chair
◇◇◇———◇
Michael Rogers
◇◇◇———◇
Ronald E. Frieson
◇◇◇———◇
Cynthia Smith
◇◇◇———◇
LeAnne M. Zumwalt
◇◇◇———◇
Myles Wolf
◇◇◇———◇
Steven C. Gilman
◇◇◇———◇
John P. Butler and Philip J. Vickers served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Ardelyx, Inc. ARDX
  • Coherus BioSciences, Inc. CHRS
  • Collegium Pharmaceutical, Inc. COLL
  • Enanta Pharmaceuticals, Inc. ENTA
  • Esperion Therapeutics, Inc. ESPR
  • Evolus, Inc. EOLS
  • Heron Therapeutics, Inc. HRTX
  • Karyopharm Therapeutics Inc. KPTI
  • MacroGenics, Inc. MGNX
  • Marinus Pharmaceuticals, Inc. MRNS
  • Ocular Therapeutix, Inc. OCUL
  • OptiNose, Inc. OPTN
  • Puma Biotechnology, Inc. PBYI
  • Rigel Pharmaceuticals, Inc. RIGL
  • Theravance Biopharma, Inc. TBPH
  • uniQure N.V. QURE
  • UroGen Pharma Ltd. URGN
  • Vanda Pharmaceuticals Inc. VNDA
  • Xeris Biopharma Holdings, Inc. XERS
  • Y-mAbs Therapeutics, Inc. YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 17, 2026=◇◇◇
2024June 10, 2025=◇◇◇
2023June 6, 2024=◇◇◇
2022June 6, 2023=◇◇◇
2021June 8, 2022=◇◇◇
2020June 2, 2021=◇◇◇
2019June 5, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- John Butler (President and Chief Executive Officer), FY2025 total compensation $5,652,339 (base salary $864,010) [exec_comp, SEC accession 0001517022-26-000034, filed 2026-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Akebia Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Akebia Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Akebia Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Akebia Therapeutics recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Akebia Therapeutics' disclosed peer group is defensible, who names Akebia Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
250 figures on this page: 243 cited to the filing that reported them, 7 calculated from figures it prints.
243 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001517022-26-000043
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001517022-26-000034
    DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION · Grants of Plan-Based Awards · Potential Payments Upon Termination
  3. 0001517022-25-000030
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001517022-25-000023
  5. 0001517022-24-000057
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001628280-24-011270
  7. 0001517022-23-000014
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-23-124284
  9. 0001193125-22-171529
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-21-180654
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-20-164639
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Akebia Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AKBA (accessed 2026).
Short form: data: Velarion

The paid brief for Akebia Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Akebia Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Akebia Therapeutics discloses

The companies named in AKBA's own disclosed peer group.

Ardelyx, Inc.Coherus BioSciences, Inc.Collegium Pharmaceutical, Inc.Enanta Pharmaceuticals, Inc.Esperion Therapeutics, Inc.Evolus, Inc.Heron Therapeutics, Inc.Karyopharm Therapeutics Inc.MacroGenics, Inc.Marinus Pharmaceuticals, Inc.Ocular Therapeutix, Inc.OptiNose, Inc.Puma Biotechnology, Inc.Rigel Pharmaceuticals, Inc.Theravance Biopharma, Inc.uniQure N.V.UroGen Pharma Ltd.Vanda Pharmaceuticals Inc.Xeris Biopharma Holdings, Inc.Y-mAbs Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy